Skip to main content
SpringerLink
Log in
Book cover

Gastrointestinal Oncology pp 325–377Cite as

Colon Cancer

  • Chapter
  • First Online:

  • 1831 Accesses

Abstract

Cancers of the colon represent the third leading cause of neoplasia-related morbidity and mortality in the United States and Canada (Committee CCSS 2009; Jemal et al. 2009). The lifetime risk for colon cancer is estimated to be 1 in 20 persons, with a median age of diagnosis of 71 years (Jemal et al. 2009). Over the past three decades, the overall incidence of colon cancer has diminished slightly by 2.2% in women and 2.8% in men (Jemal et al. 2008), yet there has been an increasing relative incidence of proximal, particularly cecal, colonic adenocarcinoma (Troisi et al. 1999). While this is partly explained by increased endoscopic screening, the etiology of this proximal shift is not entirely understood. Encouragingly, 5-year survival rates have notably improved over this time period, from 52% in 1975 to 65% in 2004 (Jemal et al. 2009).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Aaronson SA (1991) Growth factors and cancer. Science 254:1146–1153

    Article  CAS  PubMed  Google Scholar 

  • Abdalla EK, Vauthey JN, Ellis LM et al (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818–825; discussion 817–825

    Google Scholar 

  • Ackerman NB (1974) The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. Surgery 75:589–596

    CAS  PubMed  Google Scholar 

  • Adam R, Avisar E, Ariche A et al (2001) Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 8:347–353

    Article  CAS  PubMed  Google Scholar 

  • Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644–657; discussion 648–657

    Google Scholar 

  • Adam R, Miller R, Pitombo M et al (2007) Two-stage hepatectomy approach for initially unresectable colorectal hepatic metastases. Surg Oncol Clin North Am 16:525–536, viii

    Google Scholar 

  • Ahsan H, Neugut AI, Garbowski GC et al (1998) Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann Intern Med 128:900–905

    CAS  PubMed  Google Scholar 

  • AJCC (2010) American Joint Committee on Cancer – cancer staging manual, 7th edn. Springer, New York

    Google Scholar 

  • Alberts S, Sargent DJ, Smyrk T et al (2010) Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 28:7s

    Article  Google Scholar 

  • Allegra CJ, Jessup JM, Somerfield MR et al (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091–2096

    Article  PubMed  Google Scholar 

  • Aloia T, Sebagh M, Plasse M et al (2006) Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24:4983–4990

    Article  CAS  PubMed  Google Scholar 

  • Amichetti M, Lay G, Dessi M et al (2005) Results of whole brain radiation therapy in patients with brain metastases from colorectal carcinoma. Tumori 91:163–167

    PubMed  Google Scholar 

  • Andre T, Colin P, Louvet C et al (2003) Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 21:2896–2903

    Article  CAS  PubMed  Google Scholar 

  • Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351

    Article  CAS  PubMed  Google Scholar 

  • Andre T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109–3116

    Article  CAS  PubMed  Google Scholar 

  • Armbrust T, Sobotta M, Fuzesi L, Grabbe E, Ramadori G (2007) Chemotherapy-induced suppression to adenoma or complete suppression of the primary in patients with stage IV colorectal cancer: report of four cases. Eur J Gastroenterol Hepatol 19:988–994

    Article  PubMed  Google Scholar 

  • Arru M, Aldrighetti L, Castoldi R et al (2008) Analysis of prognostic factors influencing long-term survival after hepatic resection for metastatic colorectal cancer. World J Surg 32:93–103

    Article  PubMed  Google Scholar 

  • Asano T, McLeod RS (2002) Dietary fibre for the prevention of colorectal adenomas and carcinomas. Cochrane Database Syst Rev CD003430

    Google Scholar 

  • Atkin WS, Edwards R, Kralj-Hans I et al (2010) Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 375:1624–1633

    Article  PubMed  Google Scholar 

  • Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, Pinotti G, Bonetti A, Carreca I, Biasco G, Bonaglia L, Marini G, Iannelli A, Cortinovis D, Ferrario E, Beretta E, Lambiase A, Buzzoni R; Italian Trials in Medical Oncology (I.T.M.O.) Group (2004) Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma Cancer 100(2):279-287

    Article  CAS  PubMed  Google Scholar 

  • Ballantyne GH, Quin J (1993) Surgical treatment of liver metastases in patients with colorectal cancer. Cancer 71:4252–4266

    Article  CAS  PubMed  Google Scholar 

  • Barclay RL, Vicari JJ, Doughty AS, Johanson JF, Greenlaw RL (2006) Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. N Engl J Med 355:2533–2541

    Article  CAS  PubMed  Google Scholar 

  • Bardelli A, Siena S (2010) Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28:1254–1261

    Article  CAS  PubMed  Google Scholar 

  • Bartelt S, Momm F, Weissenberger C, Lutterbach J (2004) Patients with brain metastases from gastrointestinal tract cancer treated with whole brain radiation therapy: prognostic factors and survival. World J Gastroenterol 10:3345–3348

    PubMed  Google Scholar 

  • Bauman G, Charette M, Reid R, Sathya J (2005) Therapeutic Radiopharmaceutical Guidelines Group of Cancer Care Ontario’s Program in Evidence-based C. Radiopharmaceuticals for the palliation of painful bone metastases – a systematic review. Radiother Oncol 75:258–270

    CAS  PubMed  Google Scholar 

  • Baxter NN, Virnig DJ, Rothenberger DA, Morris AM, Jessurun J, Virnig BA (2005) Lymph node evaluation in colorectal cancer patients: a population-based study. J Natl Cancer Inst 97:219–225

    Article  PubMed  Google Scholar 

  • Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L (2009) Association of colonoscopy and death from colorectal cancer. Ann Intern Med 150:1–8

    PubMed  Google Scholar 

  • Bengtsson G, Carlsson G, Hafstrom L, Jonsson PE (1981) Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 141:586–589

    Article  CAS  PubMed  Google Scholar 

  • Benoist S, Pautrat K, Mitry E, Rougier P, Penna C, Nordlinger B (2005) Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg 92:1155–1160

    Article  CAS  PubMed  Google Scholar 

  • Benson AB III, Schrag D, Somerfield MR et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408–3419

    Article  PubMed  Google Scholar 

  • Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67:2643–2648

    Article  CAS  PubMed  Google Scholar 

  • Bessa X, Balleste B, Andreu M et al (2008) A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. Clin Gastroenterol Hepatol 6:206–214

    Article  CAS  PubMed  Google Scholar 

  • Bismuth H, Adam R, Levi F et al (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509–520; discussion 502–520

    Google Scholar 

  • Bleicher RJ, Allegra DP, Nora DT, Wood TF, Foshag LJ, Bilchik AJ (2003) Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned. Ann Surg Oncol 10:52–58

    Article  PubMed  Google Scholar 

  • Blomgren H, Lax I, Naslund I, Svanstrom R (1995) Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 34:861–870

    Article  CAS  PubMed  Google Scholar 

  • Bokemeyer C, Bondarenko I, Makhson A et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–671

    Article  CAS  PubMed  Google Scholar 

  • Bokemeyer C, Kohne C, Rougier P, Stroh C, Schlichting M, Van Cutsem E (2010) Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. [abstract 3506] J Clin Oncol 28:15s

    Google Scholar 

  • Bolton JS, Fuhrman GM (2000) Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann Surg 231:743–751

    Article  CAS  PubMed  Google Scholar 

  • Bond JH (2000) Polyp guideline: diagnosis, treatment, and surveillance for patients with colorectal polyps. Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 95:3053–3063

    Article  CAS  PubMed  Google Scholar 

  • Bowles BJ, Machi J, Limm WM et al (2001) Safety and efficacy of radiofrequency thermal ablation in advanced liver tumors. Arch Surg 136:864–869

    Article  CAS  PubMed  Google Scholar 

  • Brentnall TA, Haggitt RC, Rabinovitch PS et al (1996) Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 110:331–338

    Article  CAS  PubMed  Google Scholar 

  • Brown CJ, Raval MJ (2008) Advances in minimally invasive surgery in the treatment of colorectal cancer. Expert Rev Anticancer Ther 8:111–123

    Article  PubMed  Google Scholar 

  • Brown PD, Stafford SL, Schild SE, Martenson JA, Schiff D (1999) Metastatic spinal cord compression in patients with colorectal cancer. J Neurooncol 44:175–180

    Article  CAS  PubMed  Google Scholar 

  • Canon CL (2008) Is there still a role for double-contrast barium enema examination? Clin Gastroenterol Hepatol 6:389–392

    Article  PubMed  Google Scholar 

  • Capussotti L, Muratore A, Baracchi F et al (2008) Portal vein ligation as an efficient method of increasing the future liver remnant volume in the surgical treatment of colorectal metastases. Arch Surg 143:978–982; discussion 982

    Google Scholar 

  • Cassidy J, Tabernero J, Twelves C et al (2004) XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22:2084–2091

    Article  CAS  PubMed  Google Scholar 

  • Cassidy J, Clarke S, Diaz-Rubio E et al (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006–2012

    Article  CAS  PubMed  Google Scholar 

  • Chang CH, Timmerman R (2007) Stereotactic body radiation therapy: a comprehensive review. Am J Clin Oncol 30:637–644

    Article  PubMed  Google Scholar 

  • Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA (2007a) Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 99:433–441

    Article  PubMed  Google Scholar 

  • Chang EL, Shiu AS, Mendel E et al (2007b) Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. J Neurosurg Spine 7:151–160

    Article  PubMed  Google Scholar 

  • Chao A, Thun MJ, Connell CJ et al (2005) Meat consumption and risk of colorectal cancer. JAMA 293:172–182

    Article  CAS  PubMed  Google Scholar 

  • Chibaudel B, Maindrault-Goebel F, Lledo G et al (2009) Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 27:5727–5733

    Article  CAS  PubMed  Google Scholar 

  • Chow E, Harris K, Fan G, Tsao M, Sze WM (2007) Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 25:1423–1436

    Article  PubMed  Google Scholar 

  • Chua TC, Saxena A, Liauw W, Kokandi A, Morris DL (2010) Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol 17:492–501

    Article  PubMed  Google Scholar 

  • Clancy TE, Dixon E, Perlis R, Sutherland FR, Zinner MJ (2005) Hepatic arterial infusion after curative resection of colorectal cancer metastases: a meta-analysis of prospective clinical trials. J Gastrointest Surg 9:198–206

    Article  PubMed  Google Scholar 

  • Cole BF, Baron JA, Sandler RS et al (2007) Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 297:2351–2359

    Article  CAS  PubMed  Google Scholar 

  • Colucci G, Gebbia V, Paoletti G et al (2005) Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 23:4866–4875

    Article  CAS  PubMed  Google Scholar 

  • Committee CCSS (2009) Canadian cancer statistics 2009. Canadian Cancer Society, Toronto

    Google Scholar 

  • Compton CC (2003) Colorectal carcinoma: diagnostic, prognostic, and molecular features. Mod Pathol 16:376–388

    Article  PubMed  Google Scholar 

  • Compton CC (2006) Key issues in reporting common cancer specimens: problems in pathologic staging of colon cancer. Arch Pathol Lab Med 130:318–324

    PubMed  Google Scholar 

  • Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP (2000a) American Joint Committee on Cancer prognostic factors consensus conference: Colorectal Working Group. Cancer 88:1739–1757

    Article  CAS  PubMed  Google Scholar 

  • Compton CC, Fielding LP, Burgart LJ et al (2000b) Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:979–994

    CAS  PubMed  Google Scholar 

  • Correa P (1978) Epidemiology of polyps and cancer. Major Probl Pathol 10:126–152

    CAS  PubMed  Google Scholar 

  • Covey AM, Tuorto S, Brody LA et al (2005) Safety and efficacy of preoperative portal vein embolization with polyvinyl alcohol in 58 patients with liver metastases. AJR Am J Roentgenol 185:1620–1626

    Article  PubMed  Google Scholar 

  • Covey AM, Brown KT, Jarnagin WR et al (2008) Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg 247:451–455

    Article  PubMed  Google Scholar 

  • Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345

    Article  CAS  PubMed  Google Scholar 

  • De Gramont (2000) J Clin Oncol

    Google Scholar 

  • Di Nicolantonio F, Martini M, Molinari F et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705–5712

    Article  PubMed  CAS  Google Scholar 

  • Doci R, Gennari L, Bignami P, Montalto F, Morabito A, Bozzetti F (1991) One hundred patients with hepatic metastases from colorectal cancer treated by resection: analysis of prognostic determinants. Br J Surg 78:797–801

    Article  CAS  PubMed  Google Scholar 

  • Ekbom A, Helmick C, Zack M, Adami HO (1990) Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323:1228–1233

    Article  CAS  PubMed  Google Scholar 

  • Elias D, De Baere T, Smayra T, Ouellet JF, Roche A, Lasser P (2002) Percutaneous radiofrequency thermoablation as an alternative to surgery for treatment of liver tumour recurrence after hepatectomy. Br J Surg 89:752–756

    Article  CAS  PubMed  Google Scholar 

  • Elias D, Baton O, Sideris L et al (2005) Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases. J Surg Oncol 90:36–42

    Article  PubMed  Google Scholar 

  • Fairchild A, Chow E (2007) Role of radiation therapy and radiopharmaceuticals in bone metastases. Curr Opin Support Palliat Care 1:169–173

    Article  PubMed  Google Scholar 

  • Falcone A, Ricci S, Brunetti I et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670–1676

    Article  CAS  PubMed  Google Scholar 

  • Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759–767

    Article  CAS  PubMed  Google Scholar 

  • Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM (2004) Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 240:438–447; discussion 447–450

    Google Scholar 

  • Ferrucci JT (2006) Double-contrast barium enema: use in practice and implications for CT colonography. AJR Am J Roentgenol 187:170–173

    Article  PubMed  Google Scholar 

  • Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L (2004) Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol 22:3395–3407

    Article  PubMed  Google Scholar 

  • Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38–47

    Article  CAS  PubMed  Google Scholar 

  • Fong Y, Cohen AM, Fortner JG et al (1997) Liver resection for colorectal metastases. J Clin Oncol 15:938–946

    CAS  PubMed  Google Scholar 

  • Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318; discussion 318–321

    Google Scholar 

  • Gayowski TJ, Iwatsuki S, Madariaga JR et al (1994) Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery 116:703–710; discussion 701–710

    Google Scholar 

  • Gazelle GS, Hunink MG, Kuntz KM et al (2003) Cost-effectiveness of hepatic metastasectomy in patients with metastatic colorectal carcinoma: a state-transition Monte Carlo decision analysis. Ann Surg 237:544–555

    Article  PubMed  Google Scholar 

  • Giacchetti S, Perpoint B, Zidani N et al (2003) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18(1):136-147

    CAS  PubMed  Google Scholar 

  • Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539–1544

    Article  CAS  PubMed  Google Scholar 

  • Giardiello FM, Trimbath JD (2006) Peutz-Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol 4:408–415

    Article  PubMed  Google Scholar 

  • Giardiello FM, Brensinger JD, Tersmette AC et al (2000) Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119:1447–1453

    Article  CAS  PubMed  Google Scholar 

  • Giardiello FM, Brensinger JD, Petersen GM (2001) AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology 121:198–213

    Article  CAS  PubMed  Google Scholar 

  • Gill S, Loprinzi CL, Sargent DJ et al (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22:1797–1806

    Article  CAS  PubMed  Google Scholar 

  • Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN (1994) Ulcerative colitis and Crohn’s disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 35:1590–1592

    Article  CAS  PubMed  Google Scholar 

  • Giovannucci E (1995) Insulin and colon cancer. Cancer Causes Control 6:164–179

    Article  CAS  PubMed  Google Scholar 

  • Giovannucci E, Stampfer MJ, Colditz GA et al (1998) Multivitamin use, folate, and colon cancer in women in the Nurses’ Health Study. Ann Intern Med 129:517–524

    CAS  PubMed  Google Scholar 

  • Goel A, Arnold CN, Niedzwiecki D et al (2003) Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res 63:1608–1614

    CAS  PubMed  Google Scholar 

  • Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30

    Article  CAS  PubMed  Google Scholar 

  • Gomez D, Morris-Stiff G, Wyatt J, Toogood GJ, Lodge JP, Prasad KR (2008) Surgical technique and systemic inflammation influences long-term disease-free survival following hepatic resection for colorectal metastasis. J Surg Oncol 98:371–376

    Article  PubMed  Google Scholar 

  • Gray RG, Barnwell J, Hills R et al (2004) QUASAR: A randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. J Clin Oncol 22:3408–3419

    Article  Google Scholar 

  • Greenstein AJ, Sachar DB, Smith H et al (1979) Cancer in universal and left-sided ulcerative colitis: factors determining risk. Gastroenterology 77:290–294

    CAS  PubMed  Google Scholar 

  • Grothey A, Sargent D (2005) Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 23:9441–9442

    Article  PubMed  Google Scholar 

  • Grothey A, Sargent D, Goldberg RM, Schmoll HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209–1214

    Article  CAS  PubMed  Google Scholar 

  • Grothey A, Sugrue MM, Purdie DM et al (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26:5326–5334

    Article  CAS  PubMed  Google Scholar 

  • Gruenberger B, Scheithauer W, Punzengruber R, Zielinski C, Tamandl D, Gruenberger T (2008a) Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer 8:120

    Article  PubMed  CAS  Google Scholar 

  • Gruenberger B, Tamandl D, Schueller J et al (2008b) Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26:1830–1835

    Article  CAS  PubMed  Google Scholar 

  • Gunderson LL, Sosin H, Levitt S (1985) Extrapelvic colon – areas of failure in a reoperation series: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 11:731–741

    CAS  PubMed  Google Scholar 

  • Gunderson L, Martenson J, Smalley S, Garton G (1994) Lower gastrointestinal cancers: rationale, results, and techniques of treatment. Front Radiat Ther Oncol 28:140–154

    CAS  PubMed  Google Scholar 

  • Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK (2010) Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 28:264–271

    Article  PubMed  Google Scholar 

  • Haddock MG, Gunderson LL, Nelson H et al (2001) Intraoperative irradiation for locally recurrent colorectal cancer in previously irradiated patients. Int J Radiat Oncol Biol Phys 49:1267–1274

    CAS  PubMed  Google Scholar 

  • Haddock MG, Nelson H, Donohue JH et al (2003) Intraoperative electron radiotherapy as a component of salvage therapy for patients with colorectal cancer and advanced nodal metastases. Int J Radiat Oncol Biol Phys 56:966–973

    Article  PubMed  Google Scholar 

  • Haggitt RC, Glotzbach RE, Soffer EE, Wruble LD (1985) Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology 89:328–336

    CAS  PubMed  Google Scholar 

  • Hakama M, Hoff G, Kronborg O, Pahlman L (2005) Screening for colorectal cancer. Acta Oncol 44:425–439

    Article  PubMed  Google Scholar 

  • Haller DG, Catalano PJ, Macdonald JS et al (2005) Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of intergroup 0089. J Clin Oncol 23:8671–8678

    Article  PubMed  Google Scholar 

  • Haller DG, Cassidy J, Tabernero J et al (2010) Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): no impact of age on disease-free survival. In: Proceedings of the American society of clinical oncology GI cancers symposium, Orlando

    Google Scholar 

  • Hassan C, Zullo A, Risio M, Rossini FP, Morini S (2005) Histologic risk factors and clinical outcome in colorectal malignant polyp: a pooled-data analysis. Dis Colon Rectum 48:1588–1596

    Article  PubMed  Google Scholar 

  • Hecht JR, Mitchell E, Chidiac T et al (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27:672–680

    Article  CAS  PubMed  Google Scholar 

  • Heresbach D, Barrioz T, Lapalus MG et al (2008) Miss rate for colorectal neoplastic polyps: a prospective multicenter study of back-to-back video colonoscopies. Endoscopy 40:284–290

    Article  CAS  PubMed  Google Scholar 

  • Herfarth KK, Debus J (2005) Stereotactic radiation therapy for liver metastases. Chirurg 76:564–569

    Article  CAS  PubMed  Google Scholar 

  • Herfarth KK, Debus J, Lohr F et al (2001) Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 19:164–170

    CAS  PubMed  Google Scholar 

  • Hermanek P (1987) Adenoma/dysplasia –carcinoma sequence in the small intestine. Z Gastroenerol 25(3): 166-167 (German)

    CAS  Google Scholar 

  • Hewitson P, Glasziou P, Watson E, Towler B, Irwig L (2008) Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 103:1541–1549

    Article  PubMed  Google Scholar 

  • Hida J, Okuno K, Yasutomi M et al (2005) Optimal ligation level of the primary feeding artery and bowel resection margin in colon cancer surgery: the influence of the site of the primary feeding artery. Dis Colon Rectum 48:2232–2237

    Article  PubMed  Google Scholar 

  • Hughes TG, Jenevein EP, Poulos E (1983) Intramural spread of colon carcinoma. A pathologic study. Am J Surg 146:697–699

    Article  CAS  PubMed  Google Scholar 

  • Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  CAS  PubMed  Google Scholar 

  • Hurwitz HI, Fehrenbacher L, Hainsworth JD et al (2005) Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502–3508

    Article  CAS  PubMed  Google Scholar 

  • Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF (2000) Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 343:169–174

    Article  CAS  PubMed  Google Scholar 

  • International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators (1999) Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17:1356–1363

    Google Scholar 

  • Ishizuka M, Nagata H, Takagi K, Horie T, Kubota K (2007) Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg 246:1047–1051

    Article  PubMed  Google Scholar 

  • Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62

    Article  CAS  PubMed  Google Scholar 

  • Jarnagin WR, Conlon K, Bodniewicz J et al (2001) A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases. Cancer 91:1121–1128

    Article  CAS  PubMed  Google Scholar 

  • Jarnagin WR, Gonen M, Fong Y et al (2002) Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 236:397–406; discussion 397–406

    Google Scholar 

  • Jemal A, Thun MJ, Ries LA et al (2008) Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100:1672–1694

    Article  PubMed  Google Scholar 

  • Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249

    Article  PubMed  Google Scholar 

  • Jen J, Kim H, Piantadosi S et al (1994) Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331:213–221

    Article  CAS  PubMed  Google Scholar 

  • Johnson PM, Porter GA, Ricciardi R, Baxter NN (2006) Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol 24:3570–3575

    Article  PubMed  Google Scholar 

  • Jonker DJ, O’Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040–2048

    Article  CAS  PubMed  Google Scholar 

  • Kabbinavar F, Hurwitz HI, Fehrenbacher L et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60–65

    Article  CAS  PubMed  Google Scholar 

  • Kabbinavar FF, Schulz J, McCleod M et al (2005a) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23:3697–3705

    Article  CAS  PubMed  Google Scholar 

  • Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S (2005b) Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706–3712

    Article  CAS  PubMed  Google Scholar 

  • Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765

    Article  CAS  PubMed  Google Scholar 

  • Karoui M, Penna C, Amin-Hashem M et al (2006) Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243:1–7

    Article  PubMed  Google Scholar 

  • Kavanagh BD, McGarry RC, Timmerman RD (2006a) Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases. Semin Radiat Oncol 16:77–84

    Article  PubMed  Google Scholar 

  • Kavanagh BD, Schefter TE, Cardenes HR et al (2006b) Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol 45:848–855

    Article  PubMed  Google Scholar 

  • Kemeny N, Huang Y, Cohen AM et al (1999) Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 341:2039–2048

    Article  CAS  PubMed  Google Scholar 

  • Kerr D, Gray R, Quirke P et al (2009) A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study [abstract 4000]. J Clin Oncol 27:15s

    Article  Google Scholar 

  • Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87:159–170

    Article  CAS  PubMed  Google Scholar 

  • Klabunde CN, Lanier D, Breslau ES et al (2007) Improving colorectal cancer screening in primary care practice: innovative strategies and future directions. J Gen Intern Med 22:1195–1205

    Article  PubMed  Google Scholar 

  • Kohne CH, Van Cutsem E, Wils J et al (2005) Phase III Study of Weekly High-Dose Infustional Fluorouracil Plus Folinic Acid With or Without Irinotecan in Patients With Metastatic Colorectal Cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986 JCO Aug 1 4856-4865

    Article  CAS  Google Scholar 

  • Kooby DA, Stockman J, Ben-Porat L et al (2003) Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg 237:860–869; discussion 869–870

    Google Scholar 

  • Koopman M, Antonini NF, Douma J et al (2007) Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370:135–142

    Article  CAS  PubMed  Google Scholar 

  • Kopetz S, Chang GJ, Overman MJ et al (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27:3677–3683

    Article  PubMed  Google Scholar 

  • Kosari K, Gomes M, Hunter D, Hess DJ, Greeno E, Sielaff TD (2002) Local, intrahepatic, and systemic recurrence patterns after radiofrequency ablation of hepatic malignancies. J Gastrointest Surg 6:255–263

    Article  PubMed  Google Scholar 

  • Koushik A, Hunter DJ, Spiegelman D et al (2007) Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies. J Natl Cancer Inst 99:1471–1483

    Article  PubMed  Google Scholar 

  • Kritchevsky D (1995) Epidemiology of fibre, resistant starch and colorectal cancer. Eur J Cancer Prev 4:345–352

    Article  CAS  PubMed  Google Scholar 

  • Kuebler JP, Wieand HS, O’Connell MJ et al (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25:2198–2204

    Article  CAS  PubMed  Google Scholar 

  • Kuhry E, Schwenk WF, Gaupset R, Romild U, Bonjer HJ (2008) Long-term results of laparoscopic colorectal cancer resection. Cochrane Database Syst Rev CD003432

    Google Scholar 

  • Laghi L, Bianchi P, Roncalli M, Malesci A (2004) Re: revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:1402–1403; author reply 1403–1404

    Google Scholar 

  • Larsson SC, Rafter J, Holmberg L, Bergkvist L, Wolk A (2005) Red meat consumption and risk of cancers of the proximal colon, distal colon and rectum: the Swedish mammography cohort. Int J Cancer 113:829–834

    Article  CAS  PubMed  Google Scholar 

  • Laurent-Puig P, Cayre A, Manceau G et al (2009) Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27:5924–5930

    Article  CAS  PubMed  Google Scholar 

  • Lee WS, Yun HR, Yun SH et al (2008) Treatment outcomes of hepatic and pulmonary metastases from colorectal carcinoma. J Gastroenterol Hepatol 23:e367–e372

    Article  PubMed  Google Scholar 

  • Lengauer C, Kinzler KW, Vogelstein B (1997) Genetic instability in colorectal cancers. Nature 386:623–627

    Article  CAS  PubMed  Google Scholar 

  • Levi F, Zidani R, Brienza S, Dogliotti L, Perpoint B, Rotarski M, Letourneau Y, Llory JF, Chollet P, Le Rol A, Focan C (1999) A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma: International Organization for Cancer Chronotherapy. Cancer 85:2532–2540

    Article  CAS  PubMed  Google Scholar 

  • Levin B, Lieberman DA, McFarland B et al (2008) Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 58:130–160

    Article  PubMed  Google Scholar 

  • Lieberman DA, Weiss DG (2001) One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 345:555–560

    Article  CAS  PubMed  Google Scholar 

  • Liebig C, Ayala G, Wilks J et al (2009) Perineural invasion is an independent predictor of outcome in colorectal cancer. J Clin Oncol 27:5131–5137

    Article  PubMed  Google Scholar 

  • Lievre A, Bachet JB, Le Corre D et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992–3995

    Article  CAS  PubMed  Google Scholar 

  • Lindor NM, Burgart LJ, Leontovich O et al (2002) Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 20:1043–1048

    Article  CAS  PubMed  Google Scholar 

  • Lindor NM, Petersen GM, Hadley DW et al (2006) Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296:1507–1517

    Article  CAS  PubMed  Google Scholar 

  • Liu B, Nicolaides NC, Markowitz S et al (1995) Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet 9:48–55

    Article  CAS  PubMed  Google Scholar 

  • Liu B, Parsons R, Papadopoulos N et al (1996) Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med 2:169–174

    Article  CAS  PubMed  Google Scholar 

  • Locker GY, Hamilton S, Harris J et al (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24:5313–5327

    Article  CAS  PubMed  Google Scholar 

  • Logan RF, Grainge MJ, Shepherd VC, Armitage NC, Muir KR (2008) Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 134:29–38

    Article  CAS  PubMed  Google Scholar 

  • Loupakis F, Ruzzo A, Cremolini C et al (2009) KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 101:715–721

    Article  CAS  PubMed  Google Scholar 

  • Lynch HT, Smyrk T (1996) Hereditary nonpolyposis colorectal cancer (Lynch syndrome). An updated review. Cancer 78:1149–1167

    Article  CAS  PubMed  Google Scholar 

  • Lynch HT, Boland CR, Rodriguez-Bigas MA, Amos C, Lynch JF, Lynch PM (2007) Who should be sent for genetic testing in hereditary colorectal cancer syndromes? J Clin Oncol 25:3534–3542

    Article  PubMed  Google Scholar 

  • Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR (2009) Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 76:1–18

    Article  CAS  PubMed  Google Scholar 

  • MacDermed DM, Weichselbaum RR, Salama JK (2008) A rationale for the targeted treatment of oligometastases with radiotherapy. J Surg Oncol 98:202–206

    Article  PubMed  Google Scholar 

  • Machi J, Uchida S, Sumida K et al (2001) Ultrasound-guided radiofrequency thermal ablation of liver tumors: percutaneous, laparoscopic, and open surgical approaches. J Gastrointest Surg 5:477–489

    Article  CAS  PubMed  Google Scholar 

  • Mala T, Edwin B, Gladhaug I et al (2002) A comparative study of the short-term outcome following open and laparoscopic liver resection of colorectal metastases. Surg Endosc 16:1059–1063

    Article  CAS  PubMed  Google Scholar 

  • Mamounas E, Wieand S, Wolmark N et al (1999) Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17:1349–1355

    CAS  PubMed  Google Scholar 

  • Mann CD, Metcalfe MS, Leopardi LN, Maddern GJ (2004) The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases. Arch Surg 139:1168–1172

    Article  PubMed  Google Scholar 

  • Martenson JA Jr, Willett CG, Sargent DJ et al (2004) Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. J Clin Oncol 22:3277–3283

    Article  CAS  PubMed  Google Scholar 

  • Mathis KL, Nelson H, Pemberton JH, Haddock MG, Gunderson LL (2008) Unresectable colorectal cancer can be cured with multimodality therapy. Ann Surg 248:592–598

    PubMed  Google Scholar 

  • Mcleary N, Meyerhardt J, Green E et al (2009) Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients with stage II/IIII colon cancer: findings from the ACCENT database. Proc Am Soc Clin Oncol

    Google Scholar 

  • Mendez Romero A, Wunderink W, Hussain SM et al (2006) Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I–II study. Acta Oncol 45:831–837

    Article  PubMed  Google Scholar 

  • Mentha G, Terraz S, Morel P et al (2009) Dangerous halo after neoadjuvant chemotherapy and two-step hepatectomy for colorectal liver metastases. Br J Surg 96:95–103

    Article  CAS  PubMed  Google Scholar 

  • Minagawa M, Makuuchi M, Torzilli G et al (2000) Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg 231:487–499

    Article  CAS  PubMed  Google Scholar 

  • Moertel CG, Fleming TR, Macdonald JS et al (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352–358

    Article  CAS  PubMed  Google Scholar 

  • Moertel CG, Fleming TR, Macdonald JS et al (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122:321–326

    CAS  PubMed  Google Scholar 

  • Montagnani F, Chiriatti A, Turrisi G, Francini G, Fiorentini G (2010) A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity. Colorectal Dis

    Google Scholar 

  • Mulhall BP, Veerappan GR, Jackson JL (2005) Meta-analysis: computed tomographic colonography. Ann Intern Med 142:635–650

    PubMed  Google Scholar 

  • Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L (2005) Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg 242:158–171

    Article  PubMed  Google Scholar 

  • Muto T, Bussey HJ, Morson BC (1975) The evolution of cancer of the colon and rectum. Cancer 36(6): 2251-2270

    Article  CAS  PubMed  Google Scholar 

  • Neal CP, Mann CD, Sutton CD et al (2009) Evaluation of the prognostic value of systemic inflammation and socioeconomic deprivation in patients with resectable colorectal liver metastases. Eur J Cancer 45:56–64

    Article  CAS  PubMed  Google Scholar 

  • Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007–1016

    Article  CAS  PubMed  Google Scholar 

  • O’Brien MJ, Winawer SJ, Zauber AG et al (1990) The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 98:371–379

    PubMed  Google Scholar 

  • O’Connell MJ, Mailliard JA, Kahn MJ et al (1997) Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246–250

    PubMed  Google Scholar 

  • Odom SR, Duffy SD, Barone JE, Ghevariya V, McClane SJ (2005) The rate of adenocarcinoma in endoscopically removed colorectal polyps. Ann Surg 71(12): 1024-1026

    Google Scholar 

  • Offerhaus GJ, Giardiello FM, Krush AJ et al (1992) The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology 102:1980–1982

    CAS  PubMed  Google Scholar 

  • Ogino S, Nosho K, Irahara N et al (2009a) Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. J Clin Oncol 27:4591–4598

    Article  PubMed  Google Scholar 

  • Ogino S, Meyerhardt JA, Irahara N et al (2009b) KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 15:7322–7329

    Article  CAS  PubMed  Google Scholar 

  • Olsen CC, Welsh J, Kavanagh BD et al (2009) Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 73:1414–1424

    CAS  PubMed  Google Scholar 

  • Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108

    Article  PubMed  Google Scholar 

  • Parks R, Gonen M, Kemeny N et al (2007) Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg 204:753–761; discussion 753–761

    Google Scholar 

  • Pawlik TM, Scoggins CR, Zorzi D et al (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241:715–722; discussion 714–722

    Google Scholar 

  • Pawlik TM, Abdalla EK, Ellis LM, Vauthey JN, Curley SA (2006) Debunking dogma: surgery for four or more colorectal liver metastases is justified. J Gastrointest Surg 10:240–248

    Article  PubMed  Google Scholar 

  • Pearson AS, Izzo F, Fleming RY et al (1999) Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg 178:592–599

    Article  CAS  PubMed  Google Scholar 

  • Peeters M, Price T, Hotko Y et al (2010) Randomized phase III study of panitumumab with FOLFIRI versus FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:15s, 2010 (suppl; abstr 3565) Proceedings of the American Society of Clinical Oncology – GI symposium: abstract 282

    Google Scholar 

  • Phillips RK, Wallace MH, Lynch PM et al (2002) A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50:857–860

    Article  CAS  PubMed  Google Scholar 

  • Popat S, Hubner R, Houlston RS (2005) Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23:609–618

    Article  CAS  PubMed  Google Scholar 

  • Popat S, Zhao D, Chen Z et al (2007) Relationship between chromosome 18q status and colorectal cancer prognosis: a prospective, blinded analysis of 280 patients. Anticancer Res 27:627–633

    PubMed  Google Scholar 

  • Portier G, Elias D, Bouche O et al (2006) Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24:4976–4982

    Article  CAS  PubMed  Google Scholar 

  • Power DG, Kemeny NE (2010) Role of adjuvant therapy after resection of colorectal cancer liver metastases. J Clin Oncol 28:2300–2309

    Article  CAS  PubMed  Google Scholar 

  • Rabeneck L, Paszat LF, Hilsden RJ et al (2008) Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. Gastroenterology 135:1899–1906

    Article  PubMed  Google Scholar 

  • Reddy SK, Morse MA, Hurwitz HI et al (2008) Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206:96–106

    Article  PubMed  Google Scholar 

  • Rees M, Tekkis PP, Welsh FK, O’Rourke T, John TG (2008) Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 247:125–135

    Article  PubMed  Google Scholar 

  • Rex DK (2006) Maximizing detection of adenomas and cancers during colonoscopy. Am J Gastroenterol 101:2866–2877

    Article  PubMed  Google Scholar 

  • Rex DK, Cutler CS, Lemmel GT et al (1997) Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 112:24–28

    Article  CAS  PubMed  Google Scholar 

  • Ribic CM, Sargent DJ, Moore MJ et al (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247–257

    Article  CAS  PubMed  Google Scholar 

  • Robert ME (2007) The malignant colon polyp: diagnosis and therapeutic recommendations. Clin Gastroenterol Hepatol 5:662–667

    Article  PubMed  Google Scholar 

  • Rodriguez-Bigas MA, Boland CR, Hamilton SR et al (1997) A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 89:1758–1762

    Article  CAS  PubMed  Google Scholar 

  • Roth AD, Tejpar S, Delorenzi M et al (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28:466–474

    Article  CAS  PubMed  Google Scholar 

  • Rouffet F, Hay JM, Vacher B et al (1994) Curative resection for left colonic carcinoma: hemicolectomy vs. segmental colectomy. A prospective, controlled, multicenter trial. French Association for Surgical Research. Dis Colon Rectum 37:651–659

    Article  CAS  PubMed  Google Scholar 

  • Ruo L, Gougoutas C, Paty PB, Guillem JG, Cohen AM, Wong WD (2003) Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg 196:722–728

    Article  PubMed  Google Scholar 

  • Saltz LB, Niedzwiecki D, Hollis D et al (2004) Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). J Clin Oncol 22:246

    Article  CAS  Google Scholar 

  • Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019

    Article  CAS  PubMed  Google Scholar 

  • Sargent DJ, Goldberg RM, Jacobson SD et al (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091–1097

    Article  CAS  PubMed  Google Scholar 

  • Sargent DJ, Marsoni S, Monges G, et al (2010) Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28(20): 3219–3226

    Article  CAS  PubMed  Google Scholar 

  • Scheithauer W, McKendrick J, Begbie S et al (2003) Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial. Ann Oncol 14:1735-1743

    Article  CAS  PubMed  Google Scholar 

  • Schmeler KM, Lynch HT, Chen LM et al (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354:261–269

    Article  CAS  PubMed  Google Scholar 

  • Schuller J, Cassidy J, Dumont E et al (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45:291–297

    Article  CAS  PubMed  Google Scholar 

  • Schussler-Fiorenza CM, Mahvi DM, Niederhuber J, Rikkers LF, Weber SM (2004) Clinical risk score correlates with yield of PET scan in patients with colorectal hepatic metastases. J Gastrointest Surg 8:150–157; discussion 157–158

    Google Scholar 

  • Sebastian S, Johnston S, Geoghegan T, Torreggiani W, Buckley M (2004) Pooled analysis of the efficacy and safety of self-expanding metal stenting in malignant colorectal obstruction. Am J Gastroenterol 99:2051–2057

    Article  PubMed  Google Scholar 

  • Seifert JK, Bottger TC, Weigel TF, Gonner U, Junginger T (2000) Prognostic factors following liver resection for hepatic metastases from colorectal cancer. Hepatogastroenterology 47:239–246

    CAS  PubMed  Google Scholar 

  • Shinya H, Wolff WI (1979) Morphology, anatomic distribution and cancer potential of colonic polyps. Ann Surg 190(6): 679-683

    Article  CAS  PubMed  Google Scholar 

  • Seymour MT, Maughan TS, Ledermann JA et al (2007) Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370:143–152

    Article  CAS  PubMed  Google Scholar 

  • Siena S, Cassidy J, Tabernero J et al (2010) Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOFLOX4 alone as first-line treatment for metastatic colorectal cancer: PRIME trial [abstract 283]. J Clin Oncol

    Google Scholar 

  • Small RM, Lubezky N, Shmueli E et al (2009) Response to chemotherapy predicts survival following resection of hepatic colo-rectal metastases in patients treated with neoadjuvant therapy. J Surg Oncol 99:93–98

    Article  PubMed  Google Scholar 

  • Sobrero AF, Aschele C, Bertino JR (1997) Fluorouracil in colorectal cancer – a tale of two drugs: implications for biochemical modulation. J Clin Oncol 15:368–381

    CAS  PubMed  Google Scholar 

  • Sobrero AF, Maurel J, Fehrenbacher L et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311–2319

    Article  CAS  PubMed  Google Scholar 

  • Solbiati L, Livraghi T, Goldberg SN et al (2001) Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 221:159–166

    Article  CAS  PubMed  Google Scholar 

  • Sorbye H, Glimelius B, Berglund Å et al (2004) Multicentre phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 22:31–38

    Article  CAS  PubMed  Google Scholar 

  • Tabernero J, Van Cutsem E, Díaz-Rubio E (2007) Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 25(33):5225–5232

    Article  CAS  PubMed  Google Scholar 

  • Tan MC, Castaldo ET, Gao F et al (2008) A prognostic system applicable to patients with resectable liver metastasis from colorectal carcinoma staged by positron emission tomography with [18F]fluoro-2-deoxy-D-glucose: role of primary tumor variables. J Am Coll Surg 206:857–868; discussion 859–868

    Google Scholar 

  • Teufel A, Steinmann S, Siebler J et al (2004) Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. BMC Cancer 4:38

    Article  PubMed  CAS  Google Scholar 

  • Thibodeau SN, Bren G, Schaid D (1993) Microsatellite instability in cancer of the proximal colon. Science 260:816–819

    Article  CAS  PubMed  Google Scholar 

  • Timmerman R, Bastasch M, Saha D, Abdulrahman R, Hittson W, Story M (2007) Optimizing dose and fractionation for stereotactic body radiation therapy. Front Radiat Ther Oncol 40:352–365

    Article  PubMed  Google Scholar 

  • Tol J, Koopman M, Cats A et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563–572

    Article  CAS  PubMed  Google Scholar 

  • Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the Reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:2

    Google Scholar 

  • Tournigand C, Cervantes A, Figer A et al (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer – a GERCOR Study. J Clin Oncol 24:394–400

    Article  CAS  PubMed  Google Scholar 

  • Troisi RJ, Freedman AN, Devesa SS (1999) Incidence of colorectal carcinoma in the U.S.: an update of trends by gender, race, age, subsite, and stage, 1975–1994. Cancer 85:1670–1676

    Article  CAS  PubMed  Google Scholar 

  • Tsao MN, Lloyd NS, Wong RKS, Rakovitch E, Chow E, Laperriere N (2005a) Radiotherapeutic management of brain metastases: a systematic review and meta-analysis. Cancer Treat Rev 31:256–273

    Article  PubMed  Google Scholar 

  • Tsao M, Lloyd N, Wong R (2005b) The Supportive Care Guidelines Group of Cancer Care Ontario’s Program in Evidence-based C. Clinical practice guideline on the optimal radiotherapeutic management of brain metastases. BMC Cancer 5:34

    Article  PubMed  Google Scholar 

  • Twelves C, Wong A, Nowacki MP et al (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696–2704

    Article  CAS  PubMed  Google Scholar 

  • Ueno H, Mochizuki H, Hashiguchi Y et al (2004) Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 127:385–394

    Article  PubMed  Google Scholar 

  • Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664

    Article  PubMed  CAS  Google Scholar 

  • Van Cutsem E, Labianca R, Bodoky G et al (2009a) Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 27:3117–3125

    Article  PubMed  CAS  Google Scholar 

  • Van Cutsem E, Kohne CH, Hitre E et al (2009b) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417

    Article  PubMed  Google Scholar 

  • Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116:1453–1456

    Article  CAS  PubMed  Google Scholar 

  • Vauthey JN, Pawlik TM, Ribero D et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065–2072

    Article  CAS  PubMed  Google Scholar 

  • Velayos FS, Loftus EV Jr, Jess T et al (2006) Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 130:1941–1949

    Article  PubMed  Google Scholar 

  • Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM (1984) The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg 199:502–508

    Article  CAS  PubMed  Google Scholar 

  • Watson P, Lin KM, Rodriguez-Bigas MA et al (1998) Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members. Cancer 83:259–266

    Article  CAS  PubMed  Google Scholar 

  • Whitlock EP, Lin JS, Liles E, Beil TL, Fu R (2008) Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 149:638–658

    PubMed  Google Scholar 

  • Wicherts DA, Miller R, de Haas RJ et al (2008) Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg 248:994–1005

    Article  PubMed  Google Scholar 

  • Willett CG, Fung CY, Kaufman DS, Efird J, Shellito PC (1993) Postoperative radiation therapy for high-risk colon carcinoma. J Clin Oncol 11:1112–1117

    CAS  PubMed  Google Scholar 

  • Williams NS, Dixon MF, Johnston D (1983) Reappraisal of the 5 centimetre rule of distal excision for carcinoma of the rectum: a study of distal intramural spread and of patients’ survival. Br J Surg 70:150–154

    Article  CAS  PubMed  Google Scholar 

  • Winawer S, Fletcher R, Rex D et al (2003) Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 124:544–560

    Article  PubMed  Google Scholar 

  • Wolin KY, Yan Y, Colditz GA, Lee IM (2009) Physical activity and colon cancer prevention: a meta-analysis. Br J Cancer 100:611–616

    Article  CAS  PubMed  Google Scholar 

  • Wolmark N, Fisher B, Rockette H et al (1988) Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 80:30–36

    Article  CAS  PubMed  Google Scholar 

  • Wolmark N, Rockette H, Fisher B et al (1993) The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11:1879–1887

    CAS  PubMed  Google Scholar 

  • Wolmark N, Yothers G, O’Connell M et al (2009) A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP protocol C-08 [abstract LBA4]. J Clin Oncol 27:18s

    Article  Google Scholar 

  • Wong SL, Mangu PB, Choti MA et al (2009) American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 28:493–508

    Article  PubMed  Google Scholar 

  • Wright FC, Gagliardi AR, Law CH et al (2008) A randomized controlled trial to improve lymph node assessment in stage II colon cancer. Arch Surg 143:1050–1055; discussion 1055

    Google Scholar 

  • Wulf J, Guckenberger M, Haedinger U et al (2006) Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol 45:838–847

    Article  PubMed  Google Scholar 

  • Ychou M, Raoul JL, Douillard JY et al (2009) A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 20:674–680

    Article  CAS  PubMed  Google Scholar 

  • Yin FF, Ryu S, Ajlouni M et al (2004) Image-guided procedures for intensity-modulated spinal radiosurgery. Technical note. J Neurosurg 101(Suppl 3):419–424

    PubMed  Google Scholar 

  • Zealley IA, Skehan SJ, Rawlinson J, Coates G, Nahmias C, Somers S (2001) Selection of patients for resection of hepatic metastases: improved detection of extrahepatic disease with FDG pet. Radiographics 21 Spec No:S55–S69

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada

    Sharlene Gill

  2. Colorectal Surgery, St. Paul’s Hospital, Vancouver, BC, Canada

    Carl Brown

  3. Radiation Oncology, Mayo Clinic, Rochester, MN, USA

    Robert Miller

  4. Surgical Oncology, Tom Baker Cancer Centre, Calgary, AB, Canada

    Oliver Bathe

Authors
  1. Sharlene Gill
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carl Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Oliver Bathe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sharlene Gill .

Editor information

Editors and Affiliations

  1. Div. Medical Oncology, University of British Columbia, West 10th Avenue 600, Vancouver, V5Z 4E6, British Columbia, Canada

    Charles D. Blanke

  2. FB 19 Zentrum der Radiologie, Klinik f. Strahlentherapie, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, Frankfurt, 60590, Germany

    Claus Rödel

  3. Evanston Northwestern Healthcare, Northwestern University, Ridge Ave. 2650, Evanston, 60201, Illinois, USA

    Mark S. Talamonti

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Gill, S., Brown, C., Miller, R., Bathe, O. (2011). Colon Cancer. In: Blanke, C., Rödel, C., Talamonti, M. (eds) Gastrointestinal Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-13306-0_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-13306-0_12

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-13305-3

  • Online ISBN: 978-3-642-13306-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation